tirzepatide and type 1 diabetes Groundbreaking Trial Testing for Tirzepatide Leads to Significant Weight

Stopping the medication removes the pharmacological support that helped achieve the transformation, leaving individuals fighting against increased appetite, reduced metabolic rate, and hormonal changes that promote weight regain

This introductory phase helps minimize nausea, fatigue, and digestive discomfort while appetite regulation begins

Studies of orforglipron (Foundayo) showed significant and sustained weight loss (at least 10% of starting weight) over 72 weeks

Any practice that plans to offer or is currently offering the compounded drugs should keep in mind that they may need to switch how and from where it obtains the medication at some point in the future